文献速递小儿泌尿与泌尿修复前列腺增生与排尿功能障碍

A型肉毒毒素膀胱内注射与电动力给药治疗儿童脊髓脊膜膨出神经源性逼尿肌过度活动的比较

Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug Administration.
PubMed 文献 · Urology · 2020-05-11

回顾性比较A型肉毒毒素膀胱内注射与电动力给药(EMDA)治疗儿童脊髓脊膜膨出所致神经源性逼尿肌过度活动(NDO)的尿失禁疗效。EMDA组14例、注射组12例,均用10 IU/kg。6个月时完全干燥率EMDA组85.7%、注射组66.6%,1年时分别为78.5%和50%。EMDA组改善更显著且疗效更持久,可在门诊无麻醉下完成。

要点

  • EMDA组6个月完全干燥率85.7%,高于注射组66.6%。
  • EMDA组1年完全干燥率78.5%,优于注射组50%。
  • EMDA为门诊无麻醉可重复的疼痛-free方法。

核心结论

  • 两组治疗后均有改善,但EMDA组改善更显著且疗效更持久。
  • BoNTA/EMDA是可行、可重复、成本效益好且无痛的门诊方法,无需麻醉。

研究设计与样本

  • 回顾性研究纳入26例脊髓脊膜膨出(MMC)合并NDO所致尿失禁患儿,男11例、女15例。
  • EMDA组14例,经电极导管膀胱内给10 IU/kg BoNTA,门诊无麻醉,脉冲电流10-20 mA持续20分钟。
  • 注射组12例,经硬性膀胱镜膀胱内注射10 IU/kg BoNTA,住院进行。

主要发现

  • 治疗6个月后,EMDA组14例中12例(85.7%)、注射组12例中8例(66.6%)在连续两次清洁间歇导尿间完全干燥。
  • 治疗1年后,EMDA组14例中11例(78.5%)、注射组12例中6例(50%)维持完全干燥。

临床怎么用

  • 对MMC所致NDO尿失禁患儿,可考虑门诊无麻醉下行BoNTA/EMDA治疗。

局限性

  • 回顾性设计,样本量较小(共26例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the outcomes of intravesical injection of botulinum toxin A (BoNTA) with intravesical electromotive drug administration (EMDA) of BoNTA on urinary incontinence secondary to neuropathic detrusor overactivity (NDO) in children with myelomeningocele (MMC). MATERIALS AND METHODS: A total of 26 children with MMC (11 boys, 15 girls) who had urinary incontinence secondary to NDO were retrospectively enrolled in the study. Patients in EMDA group (n = 14), using an electrode-catheter, 10 IU/kg of BoNTA were inserted into the bladder for EMDA without anesthesia and on an outpatient basis. The EMDA equipment was connected to the electrode of indwelling catheter and 2 dispersive electrodes, a pulsed current generator delivered 10-20 mA for 20 minutes. Patients in injection group (n = 12) were received interavesical injection of 10 IU/kg of BoNTA via rigid cystoscope on an inpatient basis. All patients had been evaluated by a voiding diary, urodynamic study, renal, and bladder ultrasounds before, 6 months and 1 year after the treatment. RESULTS: Six months after the treatment, 12 of 14 (85.7 %) and 8 of 12 (66.6%) patients in EMDA and injection groups respectively became completely dry between 2 consecutive clean intermittent catheterizations, which maintained in 11 of 14 (78.5%) of patients in EMDA group compared to 6 of 12 (50%) of patients in injection group, 1 year after the treatment. CONCLUSION: Patients in both groups improved after the treatment; however improvement in EMDA group was more prominent with better sustained effects. BoNTA/EMDA is a feasible, reproducible, cost benefit, and pain free method as an outpatient basis and no need for anesthesia.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Ladi-Seyedian SS, Sharifi-Rad L, Kajbafzadeh AM, et al. Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug Administration. Urology. 2020. PMID: 32437774. doi:10.1016/j.urology.2020.04.104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。